Skip to main content

Advertisement

SpringerLink
Log in

Treatment with anti-TNF-α antibody infliximab reduces serum IL-15 levels in patients with rheumatoid arthritis

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

The aim of this study was to analyze the change of serum cytokines and pentosidine levels in patients with rheumatoid arthritis (RA) by infliximab treatment. Twenty-three patients with RA were studied for 30 weeks on the effects of infliximab treatment. Serum levels of IL-15, IL-16, IL-17, and granulocyte–macrophage colony-stimulating factor (GM-CSF) were measured with ELISA methods and pentosidine levels were determined using high-performance liquid chromatography, both at baseline and at 14 and 30 weeks after the initial treatment with infliximab. In addition, the patients also underwent physical and routine blood examinations. The higher levels of serum IL-15 in RA patients before treatment with infliximab significantly decreased at 14 and 30 weeks after the initial treatment with infliximab, but serum IL-16, IL-17, GM-CSF, and pentosidine levels did not decrease. The serum IL-17 and GM-CSF levels remained to be a limited detectable level at the pre- and posttreatment with infliximab. Infliximab treatment significantly lowered the serum levels of IL-15 in patients with RA. IL-15 is one of the crucial cytokines affected by infliximab.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Arend WP, Dayer J-M (1995) Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 38:151–160

    Article  PubMed  CAS  Google Scholar 

  2. Zhang HG, Hyde K, Page GP, Brand JP, Zhou J, Yu S, Allison DB, Hsu HC, Mountz JD (2004) Novel tumor necrosis factor alpha-regulated genes in rheumatoid arthritis. Arthritis Rheum 50:420–431

    Article  PubMed  CAS  Google Scholar 

  3. Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN (1998) Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 41:1258–1265

    Article  PubMed  CAS  Google Scholar 

  4. Feldmann M, Maini RN (2001) Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19:163–196

    Article  PubMed  CAS  Google Scholar 

  5. Ziolkowska M, Koc A, Luszczykiewicz G, Ksiezopolska-Pietrzak K, Klimczak E, Chwalinska-Sadowska H, Maslinski W (2000) High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 164:2832–2838

    PubMed  CAS  Google Scholar 

  6. Kim KW, Cho ML, Park MK, Yoon CH, Park SH, Lee SH, Kim HY (2005) Increased interleukin-17 production via a phosphoinositide 3-kinase/Akt and nuclear factor kappaB-dependent pathway in patients with rheumatoid arthritis. Arthritis Res Ther 7(1):R139–148

    Article  PubMed  CAS  Google Scholar 

  7. Franz JK, Kolb SA, Hummel KM, Lahrtz F, Neidhart M, Aicher WK, Pap T, Gay RE, Fontana A, Gay S (1998) Interleukin-16, produced by synovial fibroblasts, mediates chemoattraction for CD4+ T lymphocytes in rheumatoid arthritis. Eur J Immunol 28:2661–2671

    Article  PubMed  CAS  Google Scholar 

  8. Klimiuk PA, Goronzy JJ, Weyand CM (1999) IL-16 as an anti-inflammatory cytokine in rheumatoid synovitis. J Immunol 162:4293–4299

    PubMed  CAS  Google Scholar 

  9. Alsalameh S, Firestein GS, Oez S, Kurrle R, Kalden JR, Burmester GR (1994) Regulation of granulocyte macrophage colony stimulating factor production by human articular chondrocytes. Induction by both tumor necrosis factor-alpha and interleukin-1, downregulation by transforming growth factor beta and upregulation by fibroblast growth factor. J Rheumatol 21:993–1002

    PubMed  CAS  Google Scholar 

  10. Hitchon CA, El-Gabalawy HS (2004) Oxidation in rheumatoid arthritis. Arthritis Res Ther 6:265–278

    Article  PubMed  Google Scholar 

  11. Kageyama Y, Ozeki T, Suzuki M, Ichikawa T, Miura T, Miyamoto S, Machida A, Nagano A (2000) Interleukin-16 in synovial fluids from cases of various types of arthritis. Joint Bone Spine 67:188–193

    PubMed  CAS  Google Scholar 

  12. Takahashi M, Kushida K, Kawana K, Ishihara C, Denda M, Inoue T, Horiuchi K (1993) Quantification of the cross-link pentosidine in serum from normal and uremic subjects. Clin Chem 39:2162–2165

    PubMed  CAS  Google Scholar 

  13. Pittoni V, Bombardieri M, Spinelli FR, Scrivo R, Alessandri C, Conti F, Spadaro A, Valesini G (2002) Anti-tumor necrosis factor (TNF) alpha treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13. Ann Rheum Dis 61:723–725

    Article  PubMed  CAS  Google Scholar 

  14. Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J (2004) Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis. J Rheumatol 31:238–242

    PubMed  CAS  Google Scholar 

  15. Ogata Y, Kukita A, Kukita T, Komine M, Miyahara A, Miyazaki S, Kohashi O (1999) A novel role of IL-15 in the development of osteoclasts: inability to replace its activity with IL-2. J Immunol 162:2754–2760

    PubMed  CAS  Google Scholar 

  16. Miranda-Carus ME, Balsa A, Benito-Miguel M, Perez de Ayala C, Martin-Mola E (2004) IL15 and the initiation of cell contact-dependent synovial fibroblast-T lymphocyte cross-talk in rheumatoid arthritis: effect of methotrexate. J Immunol 173(2):1463–1476

    PubMed  CAS  Google Scholar 

  17. Raza K, Falciani F, Curnow SJ, Ross EJ, Lee CY, Akbar AN, Lord JM, Gordon C, Buckley CD, Salmon M (2005) Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther 7:784–795

    Article  CAS  Google Scholar 

  18. Ruchatz H, Leung BP, Wei XQ, McInnes IB, Liew FY (1998) Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology. J Immunol 160:5654–5660

    PubMed  CAS  Google Scholar 

  19. Ferrari-Lacraz S, Zanelli E, Neuberg M, Donskoy E, Kim YS, Zheng XX, Hancock WW, Maslinski W, Li XC, Strom TB, Moll T (2004) Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis. J Immunol 173:5818–5826

    PubMed  CAS  Google Scholar 

  20. Arend WP, Dayer JM (1990) Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 33:305–315

    Article  PubMed  CAS  Google Scholar 

  21. Harada S, Yamamura M, Okamoto H, Morita Y, Kawashima M, Aita T, Makino H (1999) Production of interleukin-7 and interleukin-15 by fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum 42:1508–1516

    Article  PubMed  CAS  Google Scholar 

  22. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, Martin TJ, Suda T (1999) IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103:1345–1352

    Article  PubMed  CAS  Google Scholar 

  23. Takahashi M, Suzuki M, Kushida K, Miyamoto S, Inoue T (1997) Relationship between pentosidine levels in serum and urine and activity in rheumatoid arthritis. Br J Rheumatol 36:637–642

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Orthopaedic Surgery, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu,, 431-3125, Japan

    Yasunori Kageyama, Masaaki Takahashi, Eiji Torikai, Motohiro Suzuki, Tetsuya Ichikawa, Tetsuyuki Nagafusa & Akira Nagano

  2. Department of Microbiology and Immunology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Japan

    Yukio Koide

Authors
  1. Yasunori Kageyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masaaki Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eiji Torikai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Motohiro Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tetsuya Ichikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tetsuyuki Nagafusa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yukio Koide
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Akira Nagano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yasunori Kageyama.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kageyama, Y., Takahashi, M., Torikai, E. et al. Treatment with anti-TNF-α antibody infliximab reduces serum IL-15 levels in patients with rheumatoid arthritis. Clin Rheumatol 26, 505–509 (2007). https://doi.org/10.1007/s10067-006-0312-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-006-0312-4

Keywords

Search

Navigation